Business Description
Blueprint Medicines Corp
NAICS : 325412
SIC : 2834
ISIN : US09627Y1091
Description
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.61 | |||||
Equity-to-Asset | 0.27 | |||||
Debt-to-Equity | 1.48 | |||||
Debt-to-EBITDA | -2.97 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 1.49 | |||||
Beneish M-Score | -1.91 | |||||
WACC vs ROIC |
Growth Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -33.7 | |||||
3-Year Book Growth Rate | -56.2 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 52.41 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 25.37 | |||||
9-Day RSI | 33.97 | |||||
14-Day RSI | 38.27 | |||||
6-1 Month Momentum % | -7.28 | |||||
12-1 Month Momentum % | 86.31 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.71 | |||||
Quick Ratio | 3.65 | |||||
Cash Ratio | 3.13 | |||||
Days Inventory | 530.23 | |||||
Days Sales Outstanding | 53.11 | |||||
Days Payable | 150.14 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.9 | |||||
Shareholder Yield % | -3.29 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 96.19 | |||||
Operating Margin % | -97.64 | |||||
Net Margin % | -56.64 | |||||
FCF Margin % | -95.86 | |||||
ROE % | -80.57 | |||||
ROA % | -18.67 | |||||
ROIC % | -85.48 | |||||
3-Year ROIIC % | 173.48 | |||||
ROC (Joel Greenblatt) % | -151.84 | |||||
ROCE % | -19.29 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 14.51 | |||||
PB Ratio | 16.65 | |||||
Price-to-Tangible-Book | 16.23 | |||||
EV-to-EBIT | -29.31 | |||||
EV-to-EBITDA | -31.67 | |||||
EV-to-Revenue | 13.94 | |||||
EV-to-Forward-Revenue | 7.58 | |||||
EV-to-FCF | -14.55 | |||||
Price-to-Net-Current-Asset-Value | 260.83 | |||||
Earnings Yield (Greenblatt) % | -3.41 | |||||
FCF Yield % | -6.5 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Blueprint Medicines Corp Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 335.762 | ||
EPS (TTM) (€) | -3.185 | ||
Beta | 0.34 | ||
Volatility % | 48.53 | ||
14-Day RSI | 38.27 | ||
14-Day ATR (€) | 1.89985 | ||
20-Day SMA (€) | 79.684 | ||
12-1 Month Momentum % | 86.31 | ||
52-Week Range (€) | 41 - 111.05 | ||
Shares Outstanding (Mil) | 63.35 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Blueprint Medicines Corp Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Blueprint Medicines Corp Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Blueprint Medicines Corp Frequently Asked Questions
What is Blueprint Medicines Corp(STU:2L9)'s stock price today?
When is next earnings date of Blueprint Medicines Corp(STU:2L9)?
Does Blueprint Medicines Corp(STU:2L9) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |